{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=18", "query": { "condition": "Gastric Adenocarcinomas", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 632, "total_pages": 64, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastric+Adenocarcinomas&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T11:34:53.113Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07631000", "title": "A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastroesophageal-junction Cancer" ], "interventions": [ { "name": "Cadonilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-05-27", "completion_date": "2029-05-27", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07631000" }, { "nct_id": "NCT06399757", "title": "A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Cholangiocarcinoma", "Appendiceal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Gastric Adenocarcinoma", "Endometrial Adenocarcinoma", "Triple Negative Breast Cancer", "Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "APL-5125", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollo Therapeutics Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-06-18", "completion_date": "2026-07-08", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • Sarasota, Florida + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06399757" }, { "nct_id": "NCT04220827", "title": "Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Peritoneal Carcinomatosis", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-12-06", "completion_date": "2028-10-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04220827" }, { "nct_id": "NCT03819088", "title": "Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastric Carcinoma", "Liver and Intrahepatic Bile Duct Carcinoma", "Unresectable Esophageal Carcinoma", "Unresectable Pancreatic Carcinoma" ], "interventions": [ { "name": "Zinc", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 17, "start_date": "2019-04-17", "completion_date": "2022-03-22", "has_results": false, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819088" }, { "nct_id": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Hepatocellular Cancer", "Renal Cell Carcinoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Emibetuzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 97, "start_date": "2014-03-07", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2020-12-19", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082210" }, { "nct_id": "NCT02213289", "title": "PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma" ], "interventions": [ { "name": "Trastuzumab", "type": "DRUG" }, { "name": "ABT-806", "type": "DRUG" }, { "name": "Bemarituzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Standard cytotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2015-01-20", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2021-04-08", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213289" }, { "nct_id": "NCT06038578", "title": "A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "TRK-950", "type": "BIOLOGICAL" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Toray Industries, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 146, "start_date": "2023-10-04", "completion_date": "2027-10-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Santa Monica, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Arlington", "state": "Texas" }, { "city": "Bedford", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06038578" }, { "nct_id": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cervical Neoplasms", "Endometrial Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Gallbladder Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms", "Triple Negative Breast Neoplasms", "Hepatocellular Carcinoma", "Urinary Bladder Neoplasms", "Ovarian Neoplasms", "Stomach Neoplasms" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab Co-Formulation", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 611, "start_date": "2021-09-16", "completion_date": "2025-08-05", "has_results": true, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 14, "location_summary": "Anchorage, Alaska • Duarte, California • Orange, California + 11 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05007106" }, { "nct_id": "NCT05059444", "title": "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Carcinoma", "Ureter Carcinoma", "Renal Pelvis Carcinoma", "Non-small Cell Lung Cancer", "Invasive Breast Carcinoma", "Cutaneous Melanoma", "Esophageal Carcinoma", "Gastroesophageal Junction Carcinoma", "Gastric Adenocarcinoma", "Pancreatic Adenocarcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Epithelial Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Endometrial Carcinoma", "Renal Cell Carcinoma", "Rectal Adenocarcinoma", "Colon Adenocarcinoma" ], "interventions": [ { "name": "Guardant Reveal", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Guardant Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2285, "start_date": "2021-09-07", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059444" }, { "nct_id": "NCT06266299", "title": "A Study of KK2269 in Adult Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "KK2269", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2024-01-18", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-15T11:34:53.113Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Newport Beach, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06266299" } ] }